Publications

5491 Results

A multicenter phase II study of cabozantinib + nivolumab for patients with advanced angiosarcoma previously treated with a taxane (Alliance A091902)

Authors
J Olson;J Allred;S Schuetze;E Davis;A Poklepovic;M Wagner;B Waechter;R Reidel;M Xu-Welliver;S Berg;S George;S Robinson;P Googe;S DAngelo;G Schwartz
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 11503); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral
Year
2023

A022104/NRG-GI010: A RANDOMIZED PHASE II TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY TO ACHIEVE CLINICAL COMPLETE RESPONSE IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER | THE JANUS RECTAL CANCER TRIAL

Authors
JJ Smith;A Dasari;Q Shi;J Garcia-Aguilar;H Sanoff;T George;T Hong;G Yothers;P Philip;G Nelson;T Al Baghdadi;E O'Reilly;J Meyerhardt;A Shergill;N Horvat;P Romesser;W Hall
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr TPS3640); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
Year
2023
Research Committee(s)
Gastrointestinal

Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer

Authors
A Chawla;Q Shi;A Ko;M Beg;A Varghese;M Noel;M Bloomston;F Ahmed;W Frankel;J Dixon;X Carrero;A Shergill;J Crawley;O Akin;D Renouf;G Zogopoulos;J Hubbard;J Meyerhardt;E O'Reilly;C Ferrone
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr TPS4204); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
Year
2023
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/A021806

Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or without Immunotherapy for Peritoneal Mesothelioma (Alliance A092001)

Authors
A Mansfield;A Goodrich;N Foster;V Ernani;L Villaruz;P Forde;K Raghav;P Romesser;K Garbacz;L Cao;M Salvatore;A Roden;S Powell;A Shergill;P Munster;G Schwartz;T Grotz
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr TPS8603); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
Year
2023
Research Committee(s)
Early Therapeutics and Rare Cancers

A Randomized Trial of Consolidation Targeted Adjuvant Therapy with Encorafenib and Cetuximab Versus Usual Care for Patients with Stage II/III BRAF V600E Colon Cancer (Alliance A022004)

Authors
R Yaeger;Q Shi;A Dueck;E Dib;S Kazmi;O Alese;S Krishnamurthi;A Nixon;A Shergill;E O'Reilly;J Meyerhardt
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr TPS3641); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
Year
2023
Research Committee(s)
Gastrointestinal

Comparing the Prognostic and Predictive Utility of Serum Thymidine Kinase 1 and CA 15-3 in Patients with Hormone Receptor Positive Metastatic Breast Cancer Starting First-Line Endocrine Therapy in SWOG S0226

Authors
E Cobain;W Barlow;C Paoletti;M Bergqvist;A Williams;H Ritzen;R Mehta;J Gralow;G Hortobagyi;K Albain;L Pusztai;P Sharma;A Godwin;A Thompson;D Hayes;J Rae
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 1076); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
Year
2023
Research Committee(s)
Breast
Study Number(s)
S0226

Prostate-Specific Antigen at 3 & 7 months (PSA-3mo, PSA-7mo) Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Treated with Androgen Deprivation With or Without Orteronel (SWOG S1216)

Authors
M Parikh;C Tangen;M Hussain;S Gupta;Y Jo;A Harzstark;C Paller;S George;M Zibelman;H Cheng;B Maughan;J Zhang;R Pachynski;A Bryce;D Lin;D Quinn;I Thompson;T Dorff;P Lara;N Agarwal
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 5074); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
S1216

Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide

Authors
A Goldkorn;C Tangen;M Plets;D Bsteh;T Xu;J Pinski;S Ingles;T Triche;G MacVicar;D Vaena;A Crispino;D McConkey;P Lara;M Hussain;D Quinn;T Dorff;I Thompson;N Agarwal
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 5080); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
S1216

Pathologic Concordance Rate and Outcomes by Histologic Subtype in Advanced Papillary Renal Cell (pRCC) Carcinoma: an Analysis from the SWOG S1500 (PAPMET) Trial

Authors
A Tripathi;C Tangen;X Li;M Tretiokova;P Humphrey;A Adeniran;P Barata;S Gulati;C Bergerot;D Pruthi;I Thompson;P Lara;S Pal;B Shuch
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 4562); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
S1500

Chemotherapy Dose Density is Prognostic for Patients with Resectable Pancreas Cancer: A Secondary Analysis of SWOG S1505

Authors
SH Patel;S Colby;D Sohal;K Guthrie;L Kachnic;E Chiorean;A Lowy;F Rocha;P Philip;S Ahmad
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 4158); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
Year
2023
Research Committee(s)
Gastrointestinal
Study Number(s)
S1505